Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026
Globe Newswire•29/10/2026•08:00 ET
0
Key Highlights
- ➤Corvus will report third quarter 2026 financial results November 5, 2026
- ➤Conference call and webcast scheduled for 4:30 pm ET November 5
- ➤Soquelitinib is being evaluated in a registrational Phase 3 PTCL trial
- ➤Soquelitinib is also in Phase 2 atopic dermatitis and Phase 1b hidradenitis suppurativa trials
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 5, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2026 financial results.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.
Get started
Create a free account to read the full story.